Organovo Holdings, Inc. announced the hiring of Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development. Dr. Tyree has more than 20 years of management and R&D experience in the drug discovery industry in a variety of therapeutic areas at Ligand Pharmaceuticals, TorreyPines Therapeutics (previously Neurogenetics) and most recently served as SVP, Strategic Planning at HUYABIO International.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.98 USD | -5.77% | -2.00% | -11.71% |
31/05 | Organovo Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
15/04 | Organovo's fatty liver disease drug meets main goal in mid-stage study | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.71% | 13.47M | |
+43.87% | 56.65B | |
-6.89% | 39.44B | |
+38.87% | 39.03B | |
-11.17% | 26.86B | |
+13.06% | 26.75B | |
-21.12% | 19.03B | |
+1.37% | 12.28B | |
+26.42% | 12.26B | |
+27.83% | 12.04B |
- Stock Market
- Equities
- ONVO Stock
- News Organovo Holdings, Inc.
- Organovo Holdings, Inc. Announces the Hiring of Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development